The combination of CXCL9/10-DC and anti-PD-1 or anti-PD-L1 elicited robust tumor regression, resulting in complete eradication of tumors in ∼30% of the mice (Figures 6A and S6A). The gene discussed is CXCL9; the disease is neoplasm.